Contributions
Abstract: P370
Type: Poster
Abstract Category: Clinical aspects of MS - Economic burden
Background: CARE-MS II (NCT00548405) was a 2-year, phase 3, head-to-head trial of alemtuzumab versus subcutaneous interferon beta-1a (SC IFNB-1a) in patients with active relapsing-remitting multiple sclerosis (RRMS) and an inadequate response (≥1 relapse) to prior therapy at baseline.1 Compared with SC IFNB-1a, alemtuzumab demonstrated greater improvements in clinical and MRI outcomes, and significantly more alemtuzumab-treated patients achieved no evidence of disease activity.
Goal: To evaluate healthcare resource utilisation and direct costs (US dollars) over the 2-year trial period for RRMS patients randomised to either alemtuzumab or SC IFNB-1a.
Methods: Healthcare resource utilisation was a tertiary endpoint of the CARE-MS II trial. Patients" use of healthcare resources was assessed at scheduled study visits (every 3 months) utilising the Health Resource Utilisation Questionnaire (HRUQ), a patient self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilisation was collected in the following areas: admissions and stays in the hospital, rehabilitation centres, nursing homes, consultations with specialists, general practitioners, or other healthcare professionals. Direct costs in US dollars (adjusted to US 2016 medical inflation) are reported for the alemtuzumab and SC IFNB-1a treatment arms.
Results: At baseline, resource utilisation and costs were similar in the alemtuzumab and SC IFNB-1a treatment arms. At 2-years, a statistically significant difference in resource use was observed in favour of alemtuzumab, with the SC IFNB-1a arm having a higher mean number of hospital stays and days in hospital, rehabilitation centre stays and outpatient visits, and nursing home stays and outpatient visits. Higher total direct healthcare costs were observed for SC IFNB-1a versus alemtuzumab 12 mg ($18,995 vs $10,963 respectively, P=0.0256). No differences were seen with regard to visits with specialists and other healthcare professionals.
Conclusion: Direct healthcare resource utilisation and costs as measured by HRUQ in the CARE-MS II trial were decreased with alemtuzumab treatment versus SC IFNB-1a.
Reference:
1. Coles AJ, Twyman CL, Arnold DL, et al. Lancet 2012;380:1829-39.
Disclosure:
Study support: Sanofi Genzyme.
AS and LH: Employees of Sanofi Genzyme.
Abstract: P370
Type: Poster
Abstract Category: Clinical aspects of MS - Economic burden
Background: CARE-MS II (NCT00548405) was a 2-year, phase 3, head-to-head trial of alemtuzumab versus subcutaneous interferon beta-1a (SC IFNB-1a) in patients with active relapsing-remitting multiple sclerosis (RRMS) and an inadequate response (≥1 relapse) to prior therapy at baseline.1 Compared with SC IFNB-1a, alemtuzumab demonstrated greater improvements in clinical and MRI outcomes, and significantly more alemtuzumab-treated patients achieved no evidence of disease activity.
Goal: To evaluate healthcare resource utilisation and direct costs (US dollars) over the 2-year trial period for RRMS patients randomised to either alemtuzumab or SC IFNB-1a.
Methods: Healthcare resource utilisation was a tertiary endpoint of the CARE-MS II trial. Patients" use of healthcare resources was assessed at scheduled study visits (every 3 months) utilising the Health Resource Utilisation Questionnaire (HRUQ), a patient self-report tool designed to evaluate the economic impact of MS. Healthcare resource utilisation was collected in the following areas: admissions and stays in the hospital, rehabilitation centres, nursing homes, consultations with specialists, general practitioners, or other healthcare professionals. Direct costs in US dollars (adjusted to US 2016 medical inflation) are reported for the alemtuzumab and SC IFNB-1a treatment arms.
Results: At baseline, resource utilisation and costs were similar in the alemtuzumab and SC IFNB-1a treatment arms. At 2-years, a statistically significant difference in resource use was observed in favour of alemtuzumab, with the SC IFNB-1a arm having a higher mean number of hospital stays and days in hospital, rehabilitation centre stays and outpatient visits, and nursing home stays and outpatient visits. Higher total direct healthcare costs were observed for SC IFNB-1a versus alemtuzumab 12 mg ($18,995 vs $10,963 respectively, P=0.0256). No differences were seen with regard to visits with specialists and other healthcare professionals.
Conclusion: Direct healthcare resource utilisation and costs as measured by HRUQ in the CARE-MS II trial were decreased with alemtuzumab treatment versus SC IFNB-1a.
Reference:
1. Coles AJ, Twyman CL, Arnold DL, et al. Lancet 2012;380:1829-39.
Disclosure:
Study support: Sanofi Genzyme.
AS and LH: Employees of Sanofi Genzyme.